Reuters logo
BRIEF-Meridian Bioscience comments on FDA matters related to Magellan Diagnostics
June 30, 2017 / 4:07 PM / 3 months ago

BRIEF-Meridian Bioscience comments on FDA matters related to Magellan Diagnostics

June 30 (Reuters) - Meridian Bioscience Inc:

* Meridian Bioscience comments on recent FDA matters related to Magellan Diagnostics

* Meridian Bioscience Inc says FDA concluded an inspection of Magellan’s quality system on June 29, 2017

* Meridian Bioscience Inc - Magellan is committed to addressing FDA investigators’ observations. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below